Sudhir Mungee, MD
Interventional Cardiology · Peoria, ILNPI 1023113743
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 73.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $77,035 and has fallen 90.6% since, to $7,260 in 2025. Among interventional cardiology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 422 payments — averaging $346.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$107K
- Boston Scientific$15K
- Abbott$9K
- Medtronic$8K
- Penumbra, Inc.$3K
- Shockwave Medical, Inc$772
- plus $4K from 14 others
Across 7 payments — averaging $685.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$3K
- Abbott$1K
- Abiomed$459
What the payments were for
- Consulting fees$71,20349%
- Travel & lodging$55,37838%
- Food & beverage$18,97313%
- Education$840%
- Entertainment$4740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 198 | $106,834 |
| Boston Scientific | 24 | $14,544 |
| Abbott | 77 | $8,768 |
| Medtronic(2 entities) | 25 | $8,426 |
| Penumbra, Inc. | 19 | $3,075 |
| Shockwave Medical, Inc | 10 | $772 |
| Opsens Inc. | 13 | $681 |
| GE HealthCare | 8 | $666 |
| Abiomed | 12 | $627 |
| Cardiva Medical, Inc. | 12 | $604 |
| Johnson & Johnson | 3 | $353 |
| Teleflex LLC | 2 | $156 |
| Boehringer Ingelheim | 6 | $150 |
| Livanova USA, Inc. | 2 | $133 |
| Chiesi USA, Inc. | 3 | $117 |
| Cardiovascular Systems Inc. | 1 | $80 |
| Getinge USA Sales, LLC | 3 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $20 |
| Cordis US CORP. | 1 | $19 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$69,892
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$22,261
- COREVALVE EVOLUT R$7,368
- GENERAL VASCULAR ACCESS$5,411
- GENERAL - THERAPIES$4,346
- Watchman$4,000
- Indigo$3,262
- PERCLOSE PROGLIDE$1,724
- TRICLIP$1,712
- MitraClip$1,626
- SAPIEN 3 Ultra RESILIA$1,524
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$457
- Impella$419
- XARELTO$353
- SavvyWire$322
- AVVIGO Guidance System$249
- CoreValve Evolut$223
- OptoWire$212
- GENERAL VASCULAR INTERVENTION$207
- XIENCE SIERRA$171
How this compares
$146,111 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $206,352 |
| EntrestoSacubitril/Valsartan | 104 | $143,400 |
| JardianceEmpagliflozin | 63 | $93,382 |
| XareltoRivaroxaban | 37 | $44,433 |
| Repatha SureclickEvolocumab | 48 | $42,254 |
| BrilintaTicagrelor | 31 | $36,786 |
| Praluent PenAlirocumab | 28 | $14,269 |
| Atorvastatin Calcium | 431 | $3,534 |
| Metoprolol Succinate | 275 | $3,514 |
| ClopidogrelClopidogrel Bisulfate | 252 | $2,677 |
| Carvedilol | 290 | $2,303 |
| Ezetimibe | 94 | $2,187 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 81 | $2,025 |
| Rosuvastatin Calcium | 113 | $1,524 |
| Metoprolol Tartrate | 243 | $1,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $206,352151 claims |
| Boehringer IngelheimJardiance | $150 | $93,38263 claims |
| Johnson & JohnsonXarelto | $353 | $44,43337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Peoria
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.